Back to News
Market Impact: 0.25
J&J Reports Up To 94% Clinical Remission With Tremfya In 3-Year Crohn's Data
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Johnson & Johnson reported new three-year data showing sustained clinical and endoscopic remission with Tremfya in adults with active Crohn's disease. The report provides a positive long-term treatment update, but gives no response rates or other numerical results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
JNJ0.55
More News
- J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
- J&J beats earnings estimates; Middle East conflict weighs on medical-device sales
- Johnson & Johnson shares SLIDE nearly 6% despite stronger full-year forecast
- Johnson & Johnson raises 2026 guidance as quarterly sales climb
- Jim Cramer bucks all the stock market negativity with 3 buy recommendations
- Stocks making the biggest moves premarket: JPMorgan Chase, Micron, UnitedHealth & more
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- What a Concept From Nature Tells Us About How C-Suite Executives Actually Think About AI
- How to Track Earnings Call Sentiment Across Companies